Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Pepti 3.6 mg vs Zoladex in Dysfunctional Uterine Bleeding
NCT04428684Phase 1Completed
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of goserelin in dysfunctional uterine bleeding (DUB) (2 arms). Primary endpoint: Non-inferiority in terms of activity of test drug versus comparator (Endometrial thinning) at 1 year. Started Oct 2018; status: completed.
02
Drugs
goserelin
03
Conditions
dysfunctional uterine bleeding (DUB)
Beyond the preview
Go deeper on NCT04428684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428684.